All In Biotech

Drug Trial Radar · NCT07282054

Efficacy and Safety of THDB0206 Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes

A Phase 3, Randomized, Open-Label, Multicenter, Active-controlled Trial Comparing Efficacy and Safety of THDB0206 Injection With Insulin Lispro Injection Combined With Insulin Glargine Injection U-100 in Chinese Participants With Type 1 Diabetes

Last checked: Nov 19, 2026Latest source record: Dec 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 550 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

550

Actual

Start

Apr 13, 2022

Primary completion

Jan 23, 2025

Study completion Jan 24, 2025

Sponsor

Sponsor type
Industry
First posted
Dec 15, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a 26-week randomized, open-label, multicenter, active-controlled parallel group trial. The purpose of this study is to compare efficacy and safety of THDB0206 injection with insulin lispro injection combined with insulin glargine injection U-100 in Chinese participants with T1DM.

Conditions

  • Type 1 Diabetes

Interventions

  • THDB0206Drug

    Subcutaneous THDB0206 three times daily, with individualized dose adjustment.

  • Insulin LisproDrug

    Subcutaneous insulin lispro three times daily, with individualized dose adjustment.

  • Insulin GlargineDrug

    Subcutaneous insulin glargine once daily, with individualized dose adjustment.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in HbA1c at Week 26Time frame: Week 26

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nanjing Drum Tower hospital

    Nanjing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.